Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of tofacitinib in adults with psoriatic arthritis
2011-002169-39Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tofacitinib in psoriatic arthritis (PsA), sponsored by Pfizer. Primary endpoint: Long-term safety and tolerability of tofacitinib in psoriatic arthritis. Started Oct 2013; status: completed.
02
Drugs
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2011-002169-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002169-39.